"Salmeterol Xinafoate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000068299
|
| MeSH Number(s) |
D02.033.100.291.057.750 D02.092.063.291.057.750 D02.092.471.683.061.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Salmeterol Xinafoate".
Below are MeSH descriptors whose meaning is more specific than "Salmeterol Xinafoate".
This graph shows the total number of publications written about "Salmeterol Xinafoate" by people in this website by year, and whether "Salmeterol Xinafoate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 3 | 3 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Salmeterol Xinafoate" by people in Profiles.
-
Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis. Medicine (Baltimore). 2016 May; 95(20):e3702.
-
Long-Acting Beta Agonists Enhance Allergic Airway Disease. PLoS One. 2015; 10(11):e0142212.
-
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
-
The safety of long-acting ?2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013; 8:53-64.
-
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009 Aug 29; 374(9691):695-703.
-
Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009 Feb; 22(1):44-9.
-
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
-
The value of early diagnosis for effective management of chronic obstructive pulmonary disease. J Fam Pract. 2007 Oct; 56(10 Suppl Value):S1-24.
-
Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
-
Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. Am J Respir Cell Mol Biol. 2007 Feb; 36(2):254-61.